Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity by Chris Liang, Xiaobin Yuan, Zhilin Shen, Yang Wang, Lieming Ding

Get full text

Application of the ESMO Magnitude of Clinical Benefit Scale to assess the clinical benefit of antibody drug conjugates in solid cancer: a systematic descriptive analysis of phase I... by Yang Wang, Lieming Ding, Xiaobin Yuan, Zhilin Shen, Pengxiang Wu

Get full text

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study by Jing Zheng, Tao Wang, Yunpeng Yang, Jie Huang, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Huijie Wang, Shundong Cang, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Giovanni Selvaggi, Yang Wang, Shanshan Xiao, Qian Wang, Zhilin Shen, Jianya Zhou, Jianying Zhou, Li Zhang

Get full text